Characterization of antibody and selection of alternative drug therapy in hydrochlorothiazide-induced immune hemolytic anemia.
The authors report the clinical and laboratory findings of a patient who had severe immune hemolytic anemia due to hydrochlorothiazide (HCTZ). In this case, the HCTZ antibody reacted not only with other thiazide and thiazide-like drugs, but also with a chemically unrelated diuretic, ethacrynic acid. These results indicate that HCTZ antibody activity is not restricted solely to the thiazides and imply that therapy with any of the reactive drugs would be contraindicated for this patient. The serologic screening for drug reactivity may be useful for selecting alternative therapy for patients with drug-induced immune hemolytic anemia.
Shirey
R S
RS
Department of Laboratory Medicine, Johns Hopkins Hospital, Baltimore, Maryland.
Bartholomew
J
J
Bell
W
W
Pollack
B
B
Kickler
T S
TS
Ness
P M
PM
D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced* / Q000276:immunology; D000906:Antibodies / Q000032:analysis*; D004976:Ethacrynic Acid / Q000276:immunology; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects / Q000276:immunology*; D008875:Middle Aged
D000906:Antibodies; D006852:Hydrochlorothiazide; D004976:Ethacrynic Acid